GlassScriptPhysician profile
Sabena Toor
NPI 1013097088
$6,268.30
in general payments reported to CMS, 2019-2025
47 companies · $602 in 2025
The $602 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,131 · 2020: $1,173 · 2021: $104 · 2022: $1,295 · 2023: $1,083 · 2024: $880 · 2025: $602.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,520 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,520.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $966.34 | 2022-2025 | Stelara, Tremfya |
| Amgen INC. | $847.75 | 2019-2025 | Repatha |
| Takeda Pharmaceuticals U.S.A., INC. | $356.64 | 2022-2025 | Entyvio, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $322.16 | 2022-2023 | Trulance |
| Qol Medical, LLC | $319.17 | 2022-2025 | Sucraid |
| Advanced Respiratory, INC | $300.00 | 2020 | |
| Ardelyx, INC. | $268.74 | 2022-2023 | Ibsrela |
| Glaxosmithkline, LLC. | $200.92 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $175.60 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $174.25 | 2019-2025 | Dupixent |
| Vifor Pharma, INC. | $173.55 | 2019-2020 | |
| Genzyme Corporation | $156.69 | 2019-2023 | |
| Redhill Biopharma INC. | $148.81 | 2022-2023 | Talicia, Aemcolo, Movantik |
| Otsuka America Pharmaceutical, INC. | $143.05 | 2019-2020 | |
| Exact Sciences Corporation | $114.96 | 2025 | Cologuard Collection Kit |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sabena Toor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.